Lifecore Biomedical To Be Taken Private By Webster Equity Partners In Up To $663.7 Mln Deal
Lifecore Biomedical (LFCR) agreed to be acquired by Webster Equity Partners for up to $663.7 million. The deal offers $6.28 per share plus a CVR, representing a 49.5% premium. The transaction, expected to close in Q4 2026, requires shareholder and regulatory approvals. Lifecore's stock will be delisted post-closing.
How this was made
The 30-second read
Why it matters
The cash offer represents a significant premium, likely driving LFCR shares up to the offer price while the pending delisting creates a short‑term trading catalyst.
Market read
First disclosure of a $663.7 M M&A deal, creating immediate price impact for LFCR and signaling continued private‑equity interest in the biotech space.
What to watch
Potential antitrust or regulatory hurdles could delay or block the transaction.
Background
Webster Equity Partners secured financing from MidCap Financial Trust, MSD Partners, and Alcon Research to fund the acquisition.
Ticker impact
Lifecore Biomedical announced a definitive agreement to be taken private by Webster Equity Partners for up to $663.7 million, a cash premium of ~49.5% and a potential 130% premium with CVR payments.
likely upward pressure as the market prices in the cash premium and CVR upside
First‑report of a mid‑cap M&A transaction with a $6.28 per share cash offer and potential $9.67 per share consideration creates immediate valuation upside.
Market effects
Consolidation trend in the biomedical device sector may pressure peers' valuations.
Midwest biotech market sees increased M&A activity perception.
Adds to overall private‑equity driven buy‑outs in US healthcare, modest global impact.
Counterpoint
If the CVR milestones are not met, the effective purchase price could fall, creating downside risk.
Key entities
- CompanyLifecore Biomedical, Inc.
Target of the acquisition, ticker LFCR, Nasdaq-listed.
- Private Equity FirmWebster Equity Partners
Acquirer, providing cash and CVR consideration.
